Skip to content

Study · Randomized controlled trial · n = 33 · 2017

7 results

Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.

Mensberg P, Nyby S, Jørgensen PG, Storgaard H, Jensen MT, Sivertsen J, Holst JJ, Kiens B, Richter EA, Knop FK, Vilsbøll T

Diabetes, obesity & metabolism4 Nov 2016Cited by 54 (Europe PMC)

PMID27717126 (opens in a new tab)PMCIDPMC5298031 (opens in a new tab)DOI10.1111/dom.12797 (opens in a new tab)PepBankPUB-27717126
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes who exercised, liraglutide lowered HbA1c by 2.0% versus 0.3% with placebo after 16 weeks.

    In plain wordsIn people with type 2 diabetes who exercised, liraglutide lowered HbA1c much more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 33

    Comparator
    Exercise plus placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −2%
    exercise plus liraglutide
    HbA1c change
    −0.3%
    exercise plus placebo

    Source sentences

    Summary
    Glycated haemoglobin (HbA1c) levels dropped by a mean ± standard deviation of 2.0% ± 1.2% (from 8.2% ± 1.4%) in the exercise plus liraglutide group vs 0.3% ± 0.9% (from 8.0% ± 1.2%) in the exercise plus placebo group ( P < .001), and body weight was reduced more with liraglutide (-3.4 ± 2.9 kg vs -1…
    1 context sentence
    Summary · context
    Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes who exercised, liraglutide reduced body weight more than placebo (-3.4 kg versus -1.6 kg).

    In plain wordsIn people with type 2 diabetes who exercised, liraglutide reduced body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 33

    Comparator
    Exercise plus placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Body weight change
    −3.4 kg
    exercise plus liraglutide
    Body weight change
    −1.6 kg
    exercise plus placebo

    Source sentences

    Summary
    and body weight was reduced more with liraglutide (-3.4 ± 2.9 kg vs -1.6 ± 2.3 kg; P < .001).
    1 context sentence
    Summary · context
    Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes who exercised, liraglutide reduced fasting plasma glucose more than placebo (-3.4 mM versus -0.3 mM).

    In plain wordsIn people with type 2 diabetes who exercised, liraglutide reduced fasting blood glucose more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose change
    Study

    n = 33

    Comparator
    Exercise plus placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose change
    −3.4 mM
    exercise plus liraglutide
    Fasting plasma glucose change
    −0.3 mM
    exercise plus placebo

    Source sentences

    Summary
    Greater reductions in fasting plasma glucose (-3.4 ± 2.3 mM vs -0.3 ± 2.6 mM, P < .001) and systolic blood pressure (-5.4 ± 7.4 mm Hg vs -0.6 ± 11.1 mm Hg, P < .01) were seen with exercise plus liraglutide vs exercise plus placebo.
    1 context sentence
    Summary · context
    Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes who exercised, liraglutide reduced systolic blood pressure more than placebo (-5.4 versus -0.6 mm Hg).

    In plain wordsIn people with type 2 diabetes who exercised, liraglutide lowered systolic blood pressure more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure change
    Study

    n = 33

    Comparator
    Exercise plus placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Systolic blood pressure change
    −5.4 mm Hg
    exercise plus liraglutide
    Systolic blood pressure change
    −0.6 mm Hg
    exercise plus placebo

    Source sentences

    Summary
    Greater reductions in fasting plasma glucose (-3.4 ± 2.3 mM vs -0.3 ± 2.6 mM, P < .001) and systolic blood pressure (-5.4 ± 7.4 mm Hg vs -0.6 ± 11.1 mm Hg, P < .01) were seen with exercise plus liraglutide vs exercise plus placebo.
    1 context sentence
    Summary · context
    Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes who exercised, body fat fell by similar amounts with liraglutide and with placebo.

    In plain wordsIn people with type 2 diabetes who exercised, body fat fell by similar amounts with liraglutide and with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody fat change
    Study

    n = 33

    Comparator
    Exercise plus placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Body fat change
    −2.5%
    exercise plus liraglutide
    Body fat change
    −2.2%
    exercise plus placebo

    Source sentences

    Summary
    Compared with baseline, similar reductions were seen in body fat (exercise plus liraglutide: -2.5% ± 1.4% [ P < .001]; exercise plus placebo: -2.2% ± 1.9% [ P < .001])
    1 context sentence
    Summary · context
    Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes who exercised, maximum oxygen uptake rose by similar amounts with liraglutide and with placebo.

    In plain wordsIn people with type 2 diabetes who exercised, fitness (oxygen uptake) rose by similar amounts with liraglutide and with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMaximum oxygen uptake change
    Study

    n = 33

    Comparator
    Exercise plus placebo
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Maximum oxygen uptake change
    0.5 L O2/min
    exercise plus liraglutide
    Maximum oxygen uptake change
    0.4 L O2/min
    exercise plus placebo

    Source sentences

    Summary
    and similar increases were observed in maximum oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 L O2 /min [ P < .001]; exercise plus placebo: 0.4 ± 0.4 L O2 /min [ P = .002]).
    1 context sentence
    Summary · context
    Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes who exercised, quality of life increased similarly in the liraglutide and placebo groups.

    In plain wordsIn people with type 2 diabetes who exercised, quality of life rose by similar amounts with liraglutide and with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeQuality of life
    Study

    n = 33

    Comparator
    Exercise plus placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The two groups experienced similar increases in quality of life during the intervention.
    1 context sentence
    Summary · context
    Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.